- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04394936
An Explorative Psoriasis Biomarker Study
An Exploratory, Single-center, Double-blinded, Healthy Volunteer Controlled Study to Characterize Psoriasis Patients and Explore Novel Biomarkers for the Treatment Response of Psoriasis With a Multimodal Patient Profiling Approach.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Robert Rissmann, PhD
- Phone Number: +31 71 5246 438
- Email: clintrials@chdr.nl
Study Contact Backup
- Name: Jannik Rousel, MSc
- Phone Number: +31 71 7517 197
- Email: clintrials@chdr.nl
Study Locations
-
-
-
Leiden, Netherlands, 2333 CL
- Recruiting
- Centre for Human Drug Research
-
Contact:
- Robert Rissmann, PharmD, PhD
- Phone Number: +31 71 5246 400
- Email: clintrials@chdr.nl
-
Contact:
- Diana Noort
- Phone Number: +31 71 5246 400
- Email: clintrials@chdr.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria Healthy volunteers
Eligible healthy volunteers must meet all of the following inclusion criteria at screening:
- Male or non-pregnant female subjects, 18 to 75 years of age (inclusive);
- Healthy as defined by the absence of any uncontrolled active or uncontrolled chronic disease following a medical and surgical history, documentation of general symptoms, and a symptom-directed physical examination including vital signs;
- Willing to give written informed consent and willing and able to comply with the study protocol; Psoriasis patients
Eligible psoriasis patients must meet all of the following inclusion criteria at screening:
- Male or non-pregnant female subjects, 18 to 75 years of age (inclusive);
- Diagnosed with plaque psoriasis at least 6 months prior to study participation
- Willing to discontinue any psoriasis therapy other than emollients.
- Having mild (PASI ≥1 and ≤ 5) or moderate-to-severe (PASI ≥ 10) plaque psoriasis;
- Currently not using psoriasis medication and ≥ 2 plaques suitable for repeated biopsies and target lesion assessments. At least one of these lesions must be located on the extremities, preferably on the elbow or knee, with a minimal target lesion score between 6 and 9. Or, when currently using psoriasis medication and insufficient lesional skin is present, willing to discontinue treatment awaiting rescreening (see also exclusion criteria 3 for psoriatic patients);
- Willing to give written informed consent and willing and able to comply with the study protocol; Exclusion Criteria
Eligible healthy volunteers must meet none of the following exclusion criteria at screening:
- History or symptoms of any uncontrolled, significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder that may interfere with the study objectives, in the opinion of the Investigator;
- History of immunological abnormality (e.g., immune suppression, severe allergy or anaphylaxis) that may interfere with study objectives, in the opinion of the Investigator;
- Known infection requiring antibiotic therapy within the last three months prior to the study;
- Immunosuppressive or immunomodulatory treatment within 30 days prior to the study;
- Body mass index (BMI) ≤ 18.0 or ≥ 40.0 kg/m2;
- Participation in an investigational drug study within 3 months prior to screening or more than 4 times a year;
- Previous participation in an investigational drug study involving the dosing of an investigational compound targeting an immune pathway within one year prior to screening;
- Loss or donation of blood over 500 mL within three months prior to screening;
- The use of any medication or vitamin/mineral/herbal/dietary supplement within less than 5 half-lives prior to study participation, if the Investigator judges that it may interfere with the study objectives. The use of paracetamol (up to 4 g/day) is allowed;
- History of alcohol consumption exceeding 5 standard drinks per day on average within 3 months of screening. Alcohol consumption will be prohibited from at least 12 hours preceding each study visit;
- Any other condition that could interfere with the conduct of the study or the study objectives, in the opinion of the Investigator.
Psoriasis patients
Eligible psoriasis patients must meet none of the following exclusion criteria at screening:
- Having primarily erythrodermic, pustular or guttate psoriasis;
- Having medication-induced psoriasis;
- Having previously failed on anti-IL23 therapy;
Having received treatments for psoriasis within the following intervals prior to the start of the study:
- < 2 weeks for topical treatment, e.g. retinoids, corticosteroids, vitamin D analogs
- < 4 weeks for phototherapy, e.g. PUVA, PDT
- < 4 weeks for non-biologic systemic treatment, e.g. retinoids, methotrexate, cyclosporine, fumaric acid esters
- < 4 weeks for etanercept
- < 8 weeks for adalimumab
- < 3 months for anti-IL17, anti-IL12(/23) and anti-IL23 treatments
- History or symptoms of any significant uncontrolled disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder that may interfere with the study objectives, in the opinion of the Investigator, excluding psoriasis and conditions that are related to psoriasis;
- History of immunological abnormality (e.g., immune suppression, severe allergy or anaphylaxis) that may interfere with study objectives, in the opinion of the Investigator;
- Known infection requiring antibiotic therapy within the last 3 months prior to the study, including latent tuberculosis;
- Systemic immunosuppressive or immunomodulatory treatment within 30 days prior to the study;
- Body mass index (BMI) ≤ 18.0 or ≥ 40.0 kg/m2;
- Participation in an investigational drug study within 3 months prior to screening or more than 4 times a year;
- Loss or donation of blood over 500 mL within three months prior to screening;
- The use of any medication or vitamin/mineral/herbal/dietary supplement within less than 5 half-lives prior to study participation, if the Investigator judges that it may interfere with the study objectives. The use of paracetamol (up to 4 g/day) is allowed;
- History of alcohol consumption exceeding 5 standard drinks per day on average within 3 months of screening. Alcohol consumption will be prohibited from at least 12 hours preceding each study visit;
- Any other condition that could interfere with the conduct of the study or the study objectives, in the opinion of the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Healthy volunteers
Healthy volunteer cohort (observational)
|
|
Experimental: Guselkumab
Guselkumab 100 mg/ml in prefilled syringe, subcutaneous injection, administered on day 0, 28 and 84.
|
100 mg guselkumab administered subcutaneously
|
Placebo Comparator: Placebo
Sodiumchloride 0,9% solution for injection, subcutaneous injection, administered on day 0, 28 and 84.
|
Sodiumchloride 0,9% solution for injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psoriasis Area and Severity Index (PASI) Assessment
Time Frame: from day -14 to day 168
|
Psoriasis Area and Severity Index (PASI) combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease).
|
from day -14 to day 168
|
Physicians Global Assesment (PGA) Assessment
Time Frame: from day -14 to day 168
|
Physicians Global Assesment (PGA) is a 4-point scale ranging from 0 (no disease) to 4 (maximal disease).
|
from day -14 to day 168
|
Percentage body surface affected (%BSA) Assessment
Time Frame: from day -14 to day 168
|
Percentage body surface affected (%BSA) is the area of lesional skin as a percentage of the total body surface
|
from day -14 to day 168
|
digital PASI
Time Frame: from day -14 to day 168
|
Digital Psoriasis Area and Severity Index (dPASI) calculated from standardized total body photography
|
from day -14 to day 168
|
Erythema measurement of the skin
Time Frame: from day -14 to day 168
|
Redness of the skin will be determined using a colorimeter
|
from day -14 to day 168
|
Multispectral imaging
Time Frame: from day -14 to day 168
|
The redness and superficial morphology of (non-)lesional skin sites will be determined using a multispectral imaging system
|
from day -14 to day 168
|
Laser Speckle Contrast imaging
Time Frame: from day -14 to day 168
|
The cutaneous microcirculation of (non-)lesional skin sites will be monitored over a 30 second timespan with a laser speckle contrast imager
|
from day -14 to day 168
|
Thermography
Time Frame: from day -14 to day 168
|
Body surface temperature of (non-)lesional skin will be determined using a thermal imaging infrared camera
|
from day -14 to day 168
|
Patient reported outcomes
Time Frame: from day -14 to day 168
|
Patients will be asked to report on their condition through an NRS scale (0 (better)- 10 (worse)) for sleeplessness, itch and quality of life.
Additionally, patients image their lesions on a daily basis using a mobile device.
|
from day -14 to day 168
|
Activity Tracking Heartrate
Time Frame: from day -14 to day 168
|
Subjects are requested to wear a smartwatch at all times which heart rate (beats per minute)
|
from day -14 to day 168
|
Activity Tracking Steps
Time Frame: from day -14 to day 168
|
Subjects are requested to wear a smartwatch at all times which register steps (amount of steps taken)
|
from day -14 to day 168
|
Activity Tracking Sleep
Time Frame: from day -14 to day 168
|
Subjects are requested to wear a smartwatch at all times which register sleep (hrs, minutes, seconds of rest)
|
from day -14 to day 168
|
Cells/ml; Circulating immune cell subsets
Time Frame: from day -14 to day 168
|
Blood be drawn during using a venipuncture during visits and analyzed for the presence of immune cells (e.g.
CD4+ and CD8+ T-Cells) using flow cytometry
|
from day -14 to day 168
|
Circulating protein biomarkers
Time Frame: from day -14 to day 168
|
Blood be drawn during using a venipuncture during visits and analyzed for the presence of various chemokines and cytokines (e.g.
CCL20, CCL17, CXCL8)
|
from day -14 to day 168
|
Anti-drug antibodies
Time Frame: from day 0 to day 168
|
The occurrence of antibodies directed against guselkumab will be monitored during the treatment period (ng/ml)
|
from day 0 to day 168
|
Blister immune cell subsets
Time Frame: from day 0 to day 112
|
Blisters will be induced on the non-lesional skin and the blister exudate aspirated.
Blister exudate will be analyzed for the presence of immune cells (e.g.
CD4+ and CD8+ T-Cells) using flow cytometry
|
from day 0 to day 112
|
Blister protein biomarkers
Time Frame: from day 0 to day 112
|
Blisters will be induced on the non-lesional skin and blister fluid aspirated.
Blister fluid will be analyzed for the presence of various chemokines and cytokines (e.g.
CCL20, CCL17, CXCL8) (ng/ml)
|
from day 0 to day 112
|
Immunohistochemistry of biopsies
Time Frame: day 0 to day 112
|
Biopsies will be sectioned and stained for the determination of the epidermal homeostasis (proliferation, differentiation and thickness) and infiltration of cellular immune subsets (e.g.
presence of CD4 and CD8).
|
day 0 to day 112
|
Transcriptome of biopsies
Time Frame: day 0 to day 112
|
Biopsies will be analyzed with an untargeted next-generation sequencing approach.
|
day 0 to day 112
|
Cutaneous microbiome
Time Frame: from day -14 to day 112
|
The microbiome is collected by swabbing.
The abundance of bacteria is thereafter determined using next-generation sequencing.
|
from day -14 to day 112
|
Fecal microbiome
Time Frame: from day 0 to day 112
|
The bacterial composition of stool samples is determined using next-generation sequencing.
|
from day 0 to day 112
|
Skin surface biomarkers
Time Frame: from day -14 to day 112
|
Superficial protein biomarkers are samples using a FibroTx Patch.
Afterwards, these patches are extracted and the presence of protein biomarkers (e.g.
HBD-3) determined using ELISA.
|
from day -14 to day 112
|
Lipidomics of the stratum corneum
Time Frame: from day -14 to day 112
|
Tape stripping will be performed on (non-)lesional skin and lipids are subsequently extracted from the tape and analyzed using Liquid Chromatogrpahy-Mass Spectormetry.
(ng/cm2)
|
from day -14 to day 112
|
Skin barrier function
Time Frame: from day -14 to day 168
|
The trans epidermal water loss of (non-)lesional skin will be determined as function of the inside-out barrier function of the skin.
(g/m2/h)
|
from day -14 to day 168
|
Patient genotyping
Time Frame: day -14
|
A whole blood sample will be used to scan for common mutations in genes implicated in psoriasis using next-generation sequencing.
|
day -14
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHDR1806
- 2019-002383-27 (EudraCT Number)
- NL70359.028.19 (Other Identifier: Regulatory registration number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
-
University of California, San FranciscoSun Pharmaceutical Industries LimitedRecruiting
-
University Hospital, GhentKU Leuven; University GhentRecruitingPsoriasis VulgarisBelgium
Clinical Trials on Guselkumab
-
Janssen Research & Development, LLCActive, not recruitingCrohn's DiseaseUnited States, Israel, Japan, Belgium, Lebanon, Taiwan, Netherlands, Russian Federation, Korea, Republic of, Jordan, France, Portugal, Turkey, Greece, Canada, Germany, Malaysia, Belarus, Latvia, Poland, Australia, Italy, Croatia, China, United Kingdom and more
-
University of California, San FranciscoJanssen Scientific Affairs, LLCRecruiting
-
University of California, San FranciscoJanssen Biotech, Inc.Recruiting
-
Janssen-Cilag Ltd.TerminatedPsoriasisItaly, Germany, Greece
-
Janssen Research & Development, LLCWithdrawn
-
Janssen Research & Development, LLCNo longer availableAdenomatous Polyposis Coli
-
Janssen Research & Development, LLCCompleted
-
University Medical Center GroningenJanssen-Cilag Ltd.CompletedHidradenitis SuppurativaNetherlands
-
Janssen-Cilag S.p.A.Completed
-
NYU Langone HealthJanssen Scientific Affairs, LLCRecruiting